SciELO - Scientific Electronic Library Online

 
vol.12 número5Pneumonias intersticiais idiopáticas: Uma revisão da literaturaPneumonia aguda fibrinosa e organizante índice de autoresíndice de assuntosPesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Revista Portuguesa de Pneumologia

versão impressa ISSN 0873-2159

Resumo

FONSECA, João Eurico et al. Guidelines for the diagnosis and treatment of latent tuberculosis infection and active tuberculosis in patients with inflamatory joint diseases proposed for treatment with tumour necrosis factor alpha antagonists drugs. Rev Port Pneumol [online]. 2006, vol.12, n.5, pp.603-613. ISSN 0873-2159.

The Portuguese Society of Rheumatology (SPR) and the Portuguese Society of Pulmonology (SPP) have developed guidelines for the diagnosis and treatment of latent tuberculosis infection (LTBI) and active tuberculosis (AT) in patients with inflammatory joint diseases (IJD), namely rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, treated with tumour necrosis factor alpha (TNF-á) antagonists. Due to the high risk of tuberculosis (TB) in patients with IJD, LTBI and AT screening should be performed as soon as possible, ideally at the moment of IJD diagnosis. Even if TB screening was performed at the beginning of the disease, the evaluation should be repeated before starting anti-TNF-á therapy. When TB (LTBI or AT) treatment is indicated, it should be performed before the beginning of anti-TNF-á therapy. If the IJD activity requires urgent anti-TNF-á therapy, these drugs can be started after two months of antituberculosis therapy in AT cases, or after one month in LTBI cases. Chest X-ray is mandatory for all patients. If abnormal, e.g. Gohn complex, the patient should be treated as LTBI; residual lesions require the exclusion of AT and patients with history of untreated or incomplete TB treatment should be treated as LTBI. In cases of suspected active lesions, AT diagnosis should be confirmed and adequate therapy initiated. Tuberculin skin test (TST), with two units of RT23, should be performed in all patients. If induration is less than 5 mm, the test should be repeated after 1 to 2 weeks, on the opposite forearm, and should be considered negative if the result is again inferior to 5 mm. Positive TST implicates LTBI treatment. If TST is performed in immunosupressed IJD patients, LTBI treatment should be offered to the patient before starting anti-TNFá therapy, even in the presence of a negative test.

Palavras-chave : Guidelines; Portuguese Society of Rheumatology; Portuguese Society of Pulmonology; tuberculosis; anti-TNFá drugs.

        · resumo em Português     · texto em Português     · Português ( pdf )